Shares of ResMed Inc. RMD slipped 3.97% to $204.54 Tuesday, on what proved to be an all-around poor trading session for the ...

Shares of ResMed Inc. RMD rallied 3.82% to $213.00 Monday, on what proved to be an all-around rough trading session for the ...

Resmed (RMD) announced its home sleep apnea test, NightOwl, is now available across the United States. NightOwl is an FDA-cleared home sleep ...

NightOwl is now widely available across the United States. Individuals interested in NightOwl should speak with their healthcare provider for more information. To learn more, visit: https://www.resmed ...

Home CPAP device maker Resmed is launching a small, disposable wearable to help diagnose cases of obstructive sleep apnea.  | ...

SAN DIEGO – Resmed has announced that its home sleep apnea test, NightOwl, is now available across the U.S.

KeyCorp lifted their price objective on shares of ResMed from $266.00 to $280.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. JPMorgan Chase & Co ...

NightOwl, an FDA-cleared home sleep apnea test (HSAT) offers a simplified, accurate, efficient way to diagnose obstructive sleep apnea (OSA). It adds another offering to Resmed’s portfolio, which is ...

In a welcome move, ResMed saw its Relative Strength Rating rise from 65 to 78 on Tuesday. Please watch the video at Investors ...

We recently published a list of Jim Cramer is Discussing These 10 Stocks Ahead of Q1 Earnings Season. In this article, we are ...

ResMed RMD shares rallied 3.8% in the last trading session to close at $213. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This ...

F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers AG, and QIAGEN Group LeadDublin, April 08, 2025 (GLOBE NEWSWIRE) -- The "Respiratory Disease Testing ...